GSK3β: Role in therapeutic landscape and development of modulators

British Journal of Pharmacology

Volumn 160, Issue 1, 2010, Pages 1-19

  Phukan, S ^a   Babu, V S ^a   Kannoji, A ^a   Hariharan, R ^a   Balaji, V N ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

Development of modulators; GSK3 ; Therapeutic landscape

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; BEVACIZUMAB; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBOPLATIN; CAZPAULLONE; CHIR 73911; CHIR 98014; CHIR 98023; CP 70949; ENZASTAURIN; ERLOTINIB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; KUTSU 144; LITHIUM; NEU 120; NP 12; ROSCOVITINE; SAR 502250; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TAU PROTEIN; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VX 608; AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INSULIN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOMA; GLUCOSE METABOLISM; HAPLOTYPE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IC 50; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; OVARY TUMOR; PARKINSONISM; PATENT; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; TRANSITIONAL CELL CARCINOMA; ANIMAL; CARDIOMEGALY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN CONFORMATION;

AMYLOID BETA-PROTEIN; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARDIOMEGALY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYPERTENSION; INSULIN; MODELS, MOLECULAR; NEOPLASMS; OSTEOPOROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 77950941205     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00661.x     Document Type: Review

References (118)

1. Beaulieu JM, Caron MG (2008). Looking at lithium: molecular moods and complex behavior. Mol Interv 8 : 230 241.
2. Bellei B, Flori E, Izzo E, Maresca V, Picardo M (2008). GSK3β inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signalling 20 : 1750 1761.
3. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C et al. (2005). Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376 : 51 55. (Pubitemid 40202936)
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H et al. (2000). The protein data bank. Nucleic Acids Res 28 : 235 242. (Pubitemid 30047768)
5. Bhat RV, Shanley J, Correll MP (2000). l Regulationand localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 97 : 11074 11079.
6. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y et al. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278 : 45937 45945. (Pubitemid 37432740)
7. Blendy JA (2006). The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59 : 1144 1150. (Pubitemid 43912549)
8. Bordonaro M (2009). Role of Wnt signaling in the development of type 2 diabetes. Vitam Horm 80 : 563 581.
9. Bussiere DE, He M, Le VP, Jansen JM, Chin S, Martin E (2002). Charaterisation of GSK3β protein and methods of use thereof. WO 02/24893 A2.
10. Cao Q, Lu X, Feng YJ (2006). Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16 : 671 677. (Pubitemid 44091443)
11. Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B et al. (2003). Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J Neurochem 87 : 1152 1164. (Pubitemid 37492856)
12. Chen G, Huang LD, Jiang YM, Manji HK (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72 : 1327 1330. (Pubitemid 29085050)
13. Cline GW, Johnson K, Regittnig W, Perret P, Tozzo E, Xiao L et al. (2002). Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 51 : 2903 2910.
14. Cohen P (2001). The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 268 : 5001 5010.
15. Cohen P, Alessi DR, Cross DA (1997). PDK1, one of the missing links in insulin signal transduction? FEBS Lett 410 : 3 10. (Pubitemid 27283373)
16. Cohen P, Frame S (2001). The renaissance of GSK3β. Nat Rev Mol Cell Biol 2 : 769 776.
17. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43 : 1158 1164. (Pubitemid 36009369)
18. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen P (1990). The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348 : 302 308. (Pubitemid 120029093)
19. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12 : 3499 3511. (Pubitemid 28553242)
20. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR (2007). Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 12 : 957 971. (Pubitemid 46805920)
21. Doble BW, Woodgett JR (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116 : 1175 1186.
22. Dokken BB, Sloniger JA, Henriksen EJ (2005). Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 288 : E1188 E1194.
23. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 36 : 131 137. (Pubitemid 38174370)
24. Embi N, Rylatt DB, Cohen P (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107 : 519 527.
25. Engmann O, Giese KP (2009). Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's. Disease Front Mol Neurosci 2 : 2.
26. Fang CH, Li B, James JH, Yahya A, Kadeer N, Guo X et al. (2007). GSK-3{beta} activity is increased in skeletal muscle after burn injury in rats. Am J Physiol Regul Integr Comp Physiol 293 : R1545 R1551. (Pubitemid 47535773)
27. Farmer SR (2005). Regulation of PPARgamma activity during adipogenesis. Int J Obes (Lond) 29 (Suppl. 1 S13 S16.
28. Frame S, Cohen P (2001). GSK3β takes centre stage more than 20 years after its discovery. Biochem J 359 (Pt 1 1 16.
29. Frame S, Zheleva D (2006). Targeting Glycogen synthase kinase-3 in insulin signaling. Expert Opin Ther Targets 10 : 429 444.
30. Frame S, Cohen P, Biondi RM (2001). A common phosphate binding site explains the unique substrate specificity of GSK3β and its inactivation by phosphorylation. Mol Cell 7 : 1321 1327.
31. GA M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M et al. (2002). Regulation of myeloma cell growth through Akt/GSK3β/forkhead signaling pathway. Biochem Biophys Res Commun 297 : 760 764.
32. Gadakar PK, Phukan S, Dattatreya P, Balaji VN (2007). Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3beta. J Chem Inf Model 47 : 1446 1459.
33. Gomez-Ramos A, Dominguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ et al. (2006). Sodium tungstate decreases the phosphorylation of tau through GSK3β inactivation. J Neurosci Res 83 : 264 273.
34. Gould TD (2006). Targeting glycogen synthase Kinase-3 as an approach to develop novel mood-stabilizing medications. Expert Opin Ther Targets 10 : 377 392.
35. Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D (2007). Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 21 : 2427 2439.
36. Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA et al. (2003). Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52 : 21 28.
37. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147 : 58 62.
38. Hardt SE, Sadoshima J (2002). Glycogen synthase kinase 3b: a novel regulator of cardiac hypertrophy and development. Circ Res 90 : 1055 1063.
39. Hernández F, Avila J (2008). The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett 582 : 3848 3854.
40. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406 : 86 90.
41. Hong M, Lee VM (1997). Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272 : 19547 19553.
42. Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP (2003). Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem 87 : 182 194.
43. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3β to regulate cell growth. Cell 126 : 955 968.
44. Jong IY, Li X-Y, Ota I, Hu C, Kim HS, Kim NH et al. (2006). A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 8 : 1398 1406.
45. Joong MC, Ro S, Lee TG, Lee KJ, Shin D, Hyun Y-L et al. (2004). Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof. WO 04/065370 A1.
46. Jope RS, Roh MS (2006). Glycogen synthase kinase-3 (GSK3β) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7 : 1421 1434.
47. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC et al. (2008). GSK-3b targets Cdc25A for ubiquitin-mediated proteolysis and GSK-3b inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13 : 36 47.
48. Kannoji A, Phukan S, Babu VS, Balaji VN (2008). GSK3β: a master switch and a promising target. Expert Opin Ther Target 12 : 1443 1455.
49. Kerkela R, Woulfe K, Force T (2007). Glycogen synthase kinase-3b - actively inhibiting hypertrophy. Trends Cardiovasc Med 17 : 91 96.
50. Kim W, Wilson P, Morland S, Campbell I, Walsh M, Hurst T et al. (1999). β-Catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 82 : 625 629.
51. Kim WY, Zhou FQ, Zhou J, Yokota Y, Wang YM, Yoshimura T et al. (2006). Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron 52 : 981 996.
52. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93 : 8455 8459.
53. Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W et al. (2006). Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol 26 : 898 911.
54. Kotoh M, Katoh M (2006). Cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cacades. Cancer Biology & Therapy 5 : 1059 1064.
55. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ et al. (2005). Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4 : 1681 1688.
56. Krymsky MA, Kudryashov DS, Shirinsky VP, Lukas TJ, Watterson DM, Vorotnikov AV (2001). Phosphorylation of kinase-related protein (telokin) in tonic and phasic smooth muscles. J Muscle Res Cell Motil 22 : 425 437.
57. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al. (2005). GSK3β polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58 : 829 839.
58. Lather V, Jagmohan SS, Kristam R, Karthikeyan NA, Balaji VN (2008). QSAR models for prediction of glycogen synthase kinase-3beta inhibitory activity of indirubin derivatives. QSAR Combi Sci 27 : 718 728.
59. Laure-Emmanuelle Z, Wdziekonski B, Fontaine C, Villageois P, Peraldi P, Dani C (2008). Effects of GSK3β inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biol 9 : 11.
60. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL (2001). ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61 : 6583 6591.
61. Liang J, Slingerland JM (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 : 339 345.
62. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B (2004). Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145 : 2941 2949.
63. Loberg RD, Northcott CA, Watts SW, Brosius FC, 3rd. (2003). PI3-kinase-induced hyperreactivity in DOCA-salt hypertension is independent of GSK-3 activity. Hypertension 41 : 898 902.
64. Mai L, Jope RS, Li X (2002). BDNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J Neurochem 82 : 75 83.
65. Martinez A, Alonso M, Castro A, Dorronsoro I, Gelpi JL, Luque FJ et al. (2005). SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem 48 : 7103 7112.
66. Martinez A, Perez DI (2008). GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15 : 181 191.
67. Matsuda T, Zhai P, Maejima Y, Hong C, Gao S, Tian B et al. (2008). Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci 105 : 20900 20905.
68. Mazanetz MP, Fischer PM (2007). Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6 : 464 479.
69. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M et al. (2003). GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10 : 1255 1266.
70. Mendes CT, Mury FB, de Sá Moreira E, Alberto FL, Forlenza OV, Dias-Neto E et al. (2009). Lithium reduces GSK3β mRNA levels: implications for Alzheirmer Disease. Eur Arch Psychiatry Clin Neurosci 259 : 16 22.
71. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D et al. (2006). Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 403 : 288 293.
72. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, Sadoshima J (2001). Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276 : 28586 28597.
73. Mozaffari MS, Schaffer SW (2008). Effect of Pressure Overload on Cardioprotection of Mitochondrial KATP Channels and GSK-3β: Interaction With the MPT Pore. Am J Hypertension 21 : 570 575.
74. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR (2002). Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51 : 2190 2198.
75. Nowicki M, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y et al. (2008). Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol 10 : 690 699.
76. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E et al. (2003). WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A 100 : 10429 10434.
77. Pascal G, Alistair L, Mourad S, Franck S, Philippe Y (2004). Substituted 8′-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido (1,2-a)pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurogenerative diseases WO 04/078760 A1.
78. Patricia A, Day L, Leyi G (2003). Use of a GSK3β inhibitor in the manufacture of a medicament for increasing bone formation methods for increasing bone formation. WO 03/057202 A1.
79. Patel DS, Dessalew N, Iqbal P, Bharatam PV (2007). Structure-based approaches in the design of GSK-3 selective inhibitors. Curr Protein Pept Sci 8 : 352 364.
80. Patel S, Woodgett J (2008). Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 14 : 351 353.
81. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto AZ, Wang YT et al. (2008). The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153 (S1 S428 S437.
82. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J et al. (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53 : 703 717.
83. Phiel CJ, Klein PS (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41 : 789 813.
84. Polgar T, Baki A, Szendrei GI, Keseru GM (2005). Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. J Med Chem 48 : 7946 7959.
85. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R (2009). Expression analysis of E-cadherin, Slug and GSK3β in Invasive ductal carcinoma of breast. BMC Cancer 9 : 325.
86. Prasanna S, Daga PR, Xie A, Doerksen RJ (2009). Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking. J Comput Aided Mol Des 23 : 113 127.
87. Qu ZS, Tian Q, Zhou XW, Wang Q, Zhang Q, Wang JZ (2006). Mechanism of tau hyperphosphorylation in brain cortex of diabetic rats and effect of LiCl. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 : 244 248.
88. Raymond JA, Michel R, Jasbinder S, Danny L (1999). Granulatimide derivatives for use in cancer treatment. WO 99/47522 A1.
89. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR et al. (2003). Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52 : 588 595.
90. Robertson LA, Kim AJ, Werstuck GH (2006). Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3. Can J Physiol Pharmacol 84 : 39 48.
91. Rosano L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG et al. (2005). Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65 : 11649 11657.
92. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL et al. (2000). Inhibition of adipogenesis by Wnt signaling. Science 289 : 950 953.
93. Ryan KA, Pimplikar SW (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol 171 : 327 335.
94. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B (2003). Divergent roles of GSK3βand CDK5 in APP processing. Biochem Biophys Res Commun 312 : 922 929.
95. Ryves WJ, Dajani R, Pearl L, Harwood AJ (2002). Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun 290 : 967 972.
96. Sagae S, Kobayashi K, Nishioka Y, Sugimura M, Ishioka S, Nagata M et al. (1999). Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 90 : 510 515.
97. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH (2006). GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell 17 : 1834 1844.
98. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD et al. (2005). Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334 : 1365 1373.
99. Shao J, Jung C, Liu C, Sheng H (2005). Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280 : 26565 26572.
100. Sharma M, Chuang WW, Sun Z (2002). Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3- inhibition and nuclear --catenin accumulation. J Biol Chem 277 : 30935 30941.
101. Shudong W, Christopher M, Gavin W, Kenneth D, Daniella Z, Peter F (2004). Therapeutic applications of 2-substituted 4-heteroarylpyrimidines. WO 04/056368 A1.
102. Shudong W, Janice M, Darren G, Ashley C, Nicholas T, Peter F (2005). 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors. WO 05/012262 A1.
103. Smith E, Frenkel B (2005). Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem 280 : 2388 2394.
104. Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008). Glycogen synthase kinase 3 (GSK3β) in the heart: a point of integration in hypertrophic signaling and a therapeutic target? A critical analysis. Br J Pharmacol 153 : S137 S153.
105. Sung CK, Choi WS, Scalia P (1998). Insulin-stimulated glycogen synthesis in cultured hepatoma cells: differential effects of inhibitors of insulin signaling molecules. J Recept Signal Transduct Res 18 : 243 263.
106. Takashima A (2006). GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9 : 309 317.
107. Thiel A, Heinonen M, Rintahaka J, Hallikainen T, Hemmes A, Dixon DA et al. (2006). Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem 281 : 4564 4569.
108. Thierry G, Patrick L, Alistair L, Severine M, Alain N, Mourad S et al. (2003). Substituted-2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives. WO 03/027116 A2.
109. Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 : 4673 4680.
110. Tian D, Zhu M, Chen WS, Li JS, Wu RL, Wang X (2006). Role of glycogen synthase kinase 3 in squamous differentiation induced by cigarette smoke in porcine tracheobronchial epithelial cells. Food Chem Toxicol 44 : 1590 1596.
111. Toshiyuki K, Kenji F, Tokushi H (2004). Dihydropyrazolopyridine compounds. WO 04/014910 A1.
112. Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F et al. (2004). GSK3β-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 16 : 35 45.
113. Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O et al. (2009). Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett 277 : 218 226.
114. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM (2002). Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277 : 36602 36610.
115. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M et al. (2003). Multisite phosphorylation by Cdk2 and GSK3β controls cyclin E degradation. Mol Cell 12 : 381 392.
116. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T (2008). Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 149 : 2341 2351.
117. Zhao WQ, Townsend M (2009). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792 : 482 496.
118. Zhou BP, Hung MC (2005). Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle 4 : 772 776.